Birdie Bio

[Birdie Bio @birdiebio]

$TENX Chardan KOL Call

Key Takeaways:
- Prior setbacks are from poor trial design (too broad of enrollment, tolerability, mismatched endpts) rather than biology issue
- Levo lowering wedge pressure & NTproBNP serves as basis for oral thesis
- HELP study missed primary (peak exercise wedge) but that endpt is highly variable and was mistimed
- Better Ph2 signal is wedge reduction across all exercise stages + 6MWD
- Biggest risk for LEVEL Ph3 is enrolling "less sick" pts (less room for 6MWD)
- Bar: 20m+ on 6MWD, supported by secondaries (in order.... clinical worsening, then NTproBNP, then KCCQ)

https://t.co/mFBP3QoqNM

[Birdie Bio @birdiebio]

@drsprs Like the Egyptian goddess????? I don’t understand

[Birdie Bio @birdiebio]

$RAPP $XENE **Potential Buyers**

Tier 1: Epilepsy Leaders
JNJ, ABBV, NVS, AZN, Eisai, UCB, GSK, TAK

Tier 2: Specialty Neuro
AXSM, HRMY, Lundbeck, JAZZ, SUPN

Tier 3: Opportunistic
BIIB, BMY, LLY, MRK, Roche

[Birdie Bio @birdiebio]

$XENE "Entrenched" market but polypharmacy is rampant in FOS. Epilepsy is a disorder of seizures and until we have pts who are seizure free, there will always be an unmet need. So it's a deceivingly crowded space imo. FOS data usually translates well to PGTCS.

[Birdie Bio @birdiebio]

@Andre_AGTC Is it crazy to think RAPP has a higher likelihood of getting taken out at this point? Feels like XENE has been a target since I was a little child

[Birdie Bio @birdiebio]

@seedy19tron @Archimedes20311 If this becomes a beat and raise stock i will kms

[Birdie Bio @birdiebio]

$DRG $XBI LC BioPharma Catalysts

$ABBV Bretisilocin Ph2 MDD
$AMGN Court decision & readthrough from pelacarsen
$BIIB Tau ASO Ph2 detailed data at AAIC
$BMY Milvexian Ph3, Admilparant IPF, Cobenfy ADP
$Daiichi 1L NSCLC for Dato + Imfinizi combo
$GILD Ph2 UC prelim data
$JNJ Ph3 Icotyde data in PsO
$LLY Reta Ph3 CV data from TRIUMPH3
$MRK Interim Ph3 for INT in adj melanoma
$Otsuka Voyxact 24m data
$PFE 2L mCRPC?? lol
$REGN Eylea HD PFS approval
$TAK Ph2 IBD fro zasocitinib, Ph2 NT2 data
$VRTX Ph2 APOL1 data in AMKD

[Birdie Bio @birdiebio]

@Sanctuary_Bio I agree REGN needs to diversify asap but VRTX is a separate story. Alpine deal is not the reason for the gap. 2024 also a down year for deals

[Birdie Bio @birdiebio]

$ERAS Mizuho one of top 4 picks for July

[Birdie Bio @birdiebio]

$XBI 13 Novel Approvals in the US this past Q

[Birdie Bio @birdiebio]

$AVBP $ABBV $CTMX Multitude (China) MSS CRC data for CDH17 ADC program very similar to Arrivent's ARR-217.... First time RAS has been split for this class – WT pts (~50% of disease) did about double ORR vs. RAS mut pts
Sets the bar for AVBP and adds optionality to 1L EGFR Lung (cons readout)
https://t.co/fKwWv8jnxe

[Birdie Bio @birdiebio]

$ZYME deal removes key overhang on what next target could be.. starting to look cheap based on Zani BTC & GEA alone... will be able to pay back RPRX sooner than 2033, FCF +ive earlier vs cons. ADC so far so good. RR nonideal for shorts, v obvious what Oleg wants to do